CORT vs. SPOT
CORT (Corcept Therapeutics Incorporated) and SPOT (Spotify Technology S.A.) are both stocks. CORT operates in Biotechnology (Healthcare), while SPOT operates in Internet Content & Information (Communication Services). Over the past 5 years, CORT returned 29.06%/yr vs 12.34%/yr for SPOT. At a 0.20 correlation, their price movements are largely independent.
Performance
CORT vs. SPOT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CORT achieves a 129.05% return, which is significantly higher than SPOT's -20.90% return.
CORT
- 1D
- -0.25%
- 1M
- 32.36%
- YTD
- 129.05%
- 6M
- -6.34%
- 1Y
- 11.67%
- 3Y*
- 53.92%
- 5Y*
- 29.06%
- 10Y*
- 31.34%
SPOT
- 1D
- -1.87%
- 1M
- -11.64%
- YTD
- -20.90%
- 6M
- -20.64%
- 1Y
- -35.07%
- 3Y*
- 42.88%
- 5Y*
- 12.34%
- 10Y*
- —
CORT vs. SPOT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
CORT Corcept Therapeutics Incorporated | 129.05% | -30.94% | 55.14% | 59.92% | 2.58% | -24.31% | 116.20% | -9.43% | -13.36% |
SPOT Spotify Technology S.A. | -20.90% | 29.80% | 138.08% | 138.01% | -66.27% | -25.62% | 110.40% | 31.76% | -31.59% |
Correlation
The correlation between CORT and SPOT is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Apr 3, 2018 | 0.20 |
The correlation between CORT and SPOT shifts across timeframes, from 0.03 (1 year) to 0.20 (all time), reflecting how their relationship changes across market environments.
Fundamentals
CORT:
$8.32B
SPOT:
$96.13B
CORT:
$0.41
SPOT:
€12.94
CORT:
194.37
SPOT:
30.96
CORT:
96.82
SPOT:
0.34
CORT:
12.03
SPOT:
4.78
CORT:
13.05
SPOT:
10.45
CORT:
$769.10M
SPOT:
€17.60B
CORT:
$755.64M
SPOT:
€5.68B
CORT:
$3.66M
SPOT:
€2.75B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CORT vs. SPOT — Risk / Return Rank
CORT
SPOT
CORT vs. SPOT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Spotify Technology S.A. (SPOT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CORT | SPOT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.93 | ||
| Sortino ratioReturn per unit of downside risk | +1.76 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 0.88 | +0.28 |
| Calmar ratioReturn relative to maximum drawdown | 0.18 | -0.75 | +0.93 |
| Martin ratioReturn relative to average drawdown | 0.33 | -1.27 | +1.60 |
Loading charts...
Drawdowns
CORT vs. SPOT - Drawdown Comparison
The maximum CORT drawdown since its inception was -94.29%, which is greater than SPOT's maximum drawdown of -80.51%. Use the drawdown chart below to compare losses from any high point for CORT and SPOT.
Loading charts...
Drawdown Indicators
| CORT | SPOT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.29% | -80.51% | -13.78% |
Max Drawdown (1Y)Largest decline over 1 year | -64.40% | -46.80% | -17.60% |
Max Drawdown (3Y)Largest decline over 3 years | -71.85% | -46.80% | -25.05% |
Max Drawdown (5Y)Largest decline over 5 years | -71.85% | -76.39% | +4.54% |
Max Drawdown (10Y)Largest decline over 10 years | -71.85% | — | — |
Current DrawdownCurrent decline from peak | -30.21% | -40.80% | +10.59% |
Average DrawdownAverage peak-to-trough decline | -53.43% | -30.89% | -22.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.39% | 27.73% | +7.66% |
Volatility
CORT vs. SPOT - Volatility Comparison
The current volatility for Corcept Therapeutics Incorporated (CORT) is 13.61%, while Spotify Technology S.A. (SPOT) has a volatility of 16.88%. This indicates that CORT experiences smaller price fluctuations and is considered to be less risky than SPOT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CORT | SPOT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.61% | 16.88% | -3.27% |
Volatility (6M)Calculated over the trailing 6-month period | 85.06% | 37.35% | +47.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 77.18% | 45.57% | +31.61% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 74.59% | 47.59% | +27.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 67.22% | 47.34% | +19.88% |
Dividends
CORT vs. SPOT - Dividend Comparison
Neither CORT nor SPOT has paid dividends to shareholders.
Financials
CORT vs. SPOT - Financials Comparison
This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and Spotify Technology S.A.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CORT vs. SPOT - Profitability Comparison
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
SPOT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Spotify Technology S.A. reported a gross profit of 1.51B and revenue of 4.61B. Therefore, the gross margin over that period was 32.9%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
SPOT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Spotify Technology S.A. reported an operating income of 726.76M and revenue of 4.61B, resulting in an operating margin of 15.8%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
SPOT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Spotify Technology S.A. reported a net income of 732.86M and revenue of 4.61B, resulting in a net margin of 15.9%.
Frequently Asked Questions
CORT and SPOT have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SPOT has higher volatility (16.88%) compared to CORT (13.61%). In terms of maximum drawdown, CORT dropped -94.29% vs SPOT's -80.51%.
CORT currently has the higher Sharpe Ratio (0.15 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CORT and SPOT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer